Viral Infections
EU HEPATITIS PARTNER
US HEPATITIS PARTNER
US Partner
An Introduction to Viral Infections
Viruses are intracellular parasites, and are the most widespread organisms on Earth. They cause acute disease, such as gastroenteritis or influenza, or chronic disease, such as HIV or hepatitis. Emerging infections, such as SARS, MERS, avian influenza, Ebola and most recently, the devastating SARS-Cov-2 pandemic pose an increasing threat to human health. Numerous substances with antiviral activity are in clinical use. The use of protease inhibitors and highly active antiretroviral therapy has transformed the management of HIV. Promising emerging therapeutic approaches include neutralising antibodies. In addition, the current success of mRNA vaccines against SARS-Cov-2 heralds a new era of vaccinology. However, the threat of drug- and vaccine-resistant viral mutants are a major problem.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
The US Food and Drug Administration (FDA) has expanded the indication of the pangenotypic direct-acting antiviral (DAA) combination, glecaprevir/pibrentasvir (Mavyret®; AbbVie Inc., North Chicago, IL, USA), to include the treatment of acute hepatitis C virus (HCV) infection in adults ...
The World Vaccine Congress Washington 2025, 21-24 April 2025, delivered another landmark year, bringing together more than 4,000 global stakeholders from biotechnology, pharmaceuticals, government, academia and the broader global health ecosystem. The event reinforced its standing as an influential and collaborative forum in ...
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
A double-stranded DNA virus of the Orthopoxvirus family, mpox (formerly monkeypox), continues to infect people daily, following the 2022 global outbreak.1 Two clades (clade 1 and clade 2) have been identified, with the 2022 outbreak caused by a subclade of clade 2, referred to as ...
"Europe remains committed to the global fight to end polio once and for all" Polio may be a distant memory for many in Europe, but the virus is far from gone. New data reveal that vaccine-derived poliovirus type 2 (VDPV2) was ...
As 2024 draws to a close, we’re celebrating a wonderful year of content. From insightful expert Q&As and peer-reviewed articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the infectious diseases community with high-quality, easily accessible content.
In this episode, we explore how point-of-care testing is transforming the management of sexually transmitted infections (STIs). Joined by Dr Libby van Gerwen, we discuss the rising global STI rates and the role these innovative tests play in addressing the issue. We also explore the challenges current point-of-care tests face and how next-generation advancements could further transform the future of STI diagnosis and treatment.
In a real-world study from Ontario, researchers confirmed that a single dose of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine offers 58% protection against mpox infection.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
